CA98421R1055
© ACCESS Newswire
09.12.2025
XPHY
LISTED
CSE
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
News Preview
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's proprietary oral dissolvable film (ODF) drug-delivery system. The...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.12.2025
XPHY
LISTED
CSE
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
News Preview
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce it has signed a letter agreement with a European-based chemotherapy company (the "Codeveloper&...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
20.11.2025
XPHY
LISTED
CSE
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
News Preview
VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian Patent Organization (EAPO) has officially granted Patent No. 051510 (issued Nove...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
04.11.2025
XPHY
LISTED
CSE
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
News Preview
VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has received an "Intention to Grant" notification from the European Patent Office (EPO) for Europ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
30.10.2025
XPHY
LISTED
CSE
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
News Preview
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian Patent Organization (EAPO) has issued a "Readiness to Grant" notificati...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.10.2025
XPHY
LISTED
CSE
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
News Preview
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, is pleased to announce the launch of an important large-mass animal bioequivalence study for its lead product,...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.10.2025
XPHY
LISTED
CSE
BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
News Preview
VANCOUVER, BC, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) wishes to advise its shareholders, due to the Canada Post mail strike, of alternative ways to vote their shares for the upcoming annual general meeting of shareholders of the Company (the &qu...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.10.2025
XPHY
LISTED
CSE
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
News Preview
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today announced that it has completed a Track One priority patent filing with the U.S. Patent and Trademark Off...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.10.2025
XPHY
LISTED
CSE
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
News Preview
VANCOUVER, BC, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased to report a significant advancement regarding its targeted chemotherapy delivery...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.09.2025
XPHY
LISTED
CSE
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
News Preview
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to provide an update on its proprietary Cladribine sublingual thin-film drug reformulation program (BNT23...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.09.2025
XPHY
LISTED
CSE
BioNxt Solutions Announces Closing of Shares for Debt Settlement
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "Creditor") related to an aggrega...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.09.2025
XPHY
LISTED
CSE
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic Mines Inc. (TSX-V: PNPN), will continue his role as a capital markets advisor to the Company. Mr. Lynch brings decades of early-s...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
15.09.2025
XPHY
LISTED
CSE
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
News Preview
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma&qu...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.09.2025
XPHY
LISTED
CSE
BioNxt Announces Shares for Debt Settlement
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces the Company has entered into a debt settlement agreement with an arm's length credi...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2022
XPHY
LISTED
CSE
CSE Bulletin: Name and Symbol Change - XPhyto Therapeutics Corp. (XPHY)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 10 novembre/November 2022) - XPhyto Therapeutics Corp. (XPHY) has announced a name and symbol change to BioNxt Solutions Inc. (BNXT). Shares will begin trading under the new name and symbol and with a new CUSIP number on November 14, 2022. Disclosure documents are available at www.t...
Themefolio
Profiler
Peergroup
© Newsfile
25.08.2020
XPHY
LISTED
CSE
XPhyto Provides Update on Parkinsons' Transdermal Patch
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ("XPhyto" or the "Company"), a next generation bioscience company, is pleased to announce an update on its transdermal delivery system ("TDS") for the neurologic drug Rotigotine. Further to the Company's press release da...
Themefolio
Profiler
Peergroup
© Newsfile
06.07.2020
XPHY
LISTED
CSE
XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), has confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and i...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2020
XPHY
LISTED
CSE
XPhyto Engages Knox Communications Inc. for Investor Relations Services
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has entered into an investor relations consulting agreement (the "Agreement") with Knox Communications Inc. ("KCI") to carryout marketing and investor com...
Themefolio
Profiler
Peergroup
© Newsfile
15.06.2020
XPHY
LISTED
CSE
XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has successfully incorporated peptide biosensors into its oral dissolvable thin film ("ODF")...
Themefolio
Profiler
Peergroup
© Newsfile
10.06.2020
XPHY
LISTED
CSE
XPhyto's Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its diagnostic partner, 3a-Diagnostics GmbH ("3a") and their contract research collaborators, have received a €254,200 grant from the German Federal Mi...
Themefolio
Profiler
Peergroup
© Newsfile
23.03.2020
XPHY
LISTED
CSE
RETRANSMISSION: COVID-19 Test and Development Programs Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma T...
Themefolio
Profiler
Peergroup
© Newsfile
20.03.2020
XPHY
LISTED
CSE
XPhyto Announces COVID-19 Test and Development Programs Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma T...
Themefolio
Profiler
Peergroup
© Newsfile
19.03.2020
XPHY
LISTED
CSE
XPhyto Therapeutics Epilepsy Treatment Program
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the Company's press release dated December 9, 2019, titled "E...
Themefolio
Profiler
Peergroup
© Newsfile
03.03.2020
XPHY
LISTED
CSE
XPhyto Therapeutics Initiates Infectious Disease Programs
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), will be commencing several research and development programs related to infectious disease. These programs incl...
Themefolio
Profiler
Peergroup
© Newsfile
18.02.2020
XPHY
LISTED
CSE
Exclusive Strategic Partnership Commenced Between XPhyto Therapeutics and Elite Bavarian Brewing & Beverage Institute Weihenstephan
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has begun its strategic exclusive partnership for research and development of cannabis focused produc...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2020
XPHY
LISTED
CSE
XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest qual...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
